OP0274 HOSPITALISATION FOR TUBERCULOSIS AND OTHER OPPORTUNISTIC INFECTIONS IN PATIENTS WITH INFLAMMATORY JOINT DISEASES BEFORE AND AFTER THE INTRODUCTION OF BIOLOGICAL THERAPY.
Authors: J. Nossent, H. Keen, D. Preen, C. Inderjeeth
Journal: Annals of the Rheumatic Diseases (2022)

Background Over the last 20 years aggressive therapy for inflammatory joint diseases (IJD) has become standard of care following the acceptance of Methotrexate as anchor drug and extensive of use biologic therapy since 2003. Immunosuppression increases the risk for common and uncommon infections (1). Objectives To compare the temporal rates and associated mortality of hospitalisation with opportunistic infections (OI) (Table 1) for IJD patients in Western Australia between 1985 and 2015. Methods All patients hospitalized in Western Australia in the period 1980-2015 with ≥ 2 diagnostic codes for rheumatoid arthritis (RA, n=8490), psoriatic arthritis (PsA, n=601), axial spondylarthritis (AS, n=1419). Overall incidence rates (IR) with microbiologically confirmed OI (Mycobacterial, Fungal and viral infections)(Table 1) during 306.514 person years were expressed per 1000 person years and compared across IJD by incidence rate ratios (IRR) with 95% CI. IR trend rates across 5-year periods for each IJD were analyzed by least square regression (R 2 ). Mortality rate ratio (MRR) was number of deaths per 1000 observation years in patients with OI compared to patients in same disease category hospitalized without OI. Table 1. Diagnostic codes applied to define conditions and opportunistic infections in hospital discharge database. ICD9CM ICD10AM RA 714.0-714.9 M05.0-M06.9 AS 720.0 M45, M08.10-M08.19 PsA 696.0 M07.0-M07.3, L40.5 Tuberculosis 010.x-018.x A15–A19 Non-tuberculous mycobacteria 031.x A30-A31 Cryptococcosis 117.5 B45 Aspergillosis 117.3 B44 Histoplasmosis 115 B39 All mycosis 114.0 - 118.9 B35.0 - B49.9 Pneumocystosis 136.3 B59 Cytomegaloviral disease 078.5 B25 Influenza 487.x, 488.x J09, J10 Herpes zoster 053.x B02 Varicella 052.x B01 Results The IR for all OI in RA patients (5.19, CI 4.8-5.6) was significantly higher than for PsA (IRR 0.56, CI 0.41-0.76 and AS (IRR 0.64, CI 0.53-0.79) with lower IRR observed especially for tuberculosis and H Zoster in PsA (0,49 and 0,47) and AS patients (0,43 and 0,49). H Zoster, TBC and other mycobacteria were the most frequent cause of OI with cryptococcal and pneumocystis only seen in RA. The IR for TBC decreased over time in RA (R 2 0.51, p=0.08), and AS (R 2 0.47, p=0.09) while the IR for H. zoster decreased in RA only (R 2 0.46, p=0.09) (Figure 1). In-hospital mortality rate in patients with OI was 4.9 % for RA, 2.6 % for PsA and 2.2% for AS, but MRR for RA (1.15; 0.71-1.97), PsA (1.64; 0.82-3.57) and AS patients (1.35; 0.68-2.89) was not significantly increased. Figure 1. Incidence rate per 1000 personyears over time for hospitalisation with opportunistic infections in RA patients. Conclusion The IR for hospitalization with OI is twice as high for RA patients compared to AS and PsA patients. Admission rates for most OI including have decreased in RA patients over the two decades where more intensive treatment became standard of care. This suggests efficacy of preventative measures. Hospital admission with OI associated with a moderate risk of death, but did not incur a higher risk of death than admission for other medical complications in IJD patients References [1]Wang D, Yeo AL, Dendle C, Morton S, Morand E, Leech M. Severe infections remain common in a real-world rheumatoid arthritis cohort: A simple clinical model to predict infection risk. Eur J Rheumatol 2021; 8(3): 133-8. Acknowledgements Supported by an unrestricted grant from the Arthritis Foundation of Western Australia. Disclosure of Interests None declared